MANAGED ACCESS:
NAME PATIENT PROGRAMMES
We set up paid market access programmes for innovative specialty medicines:
- A comprehensive package of services put in place to ethically address unsolicited requests from healthcare providers for paid access Named Patient Programmes (NPPs);
- An exclusive and centralized access route with regulatory, compliance, payer and funding solutions as well as a global logistics and distribution infrastructure.
The Group offers both paid access and pro-bono (compassionate) access programmes through a comprehensive service package with a fair financial structure and flexible commercial terms to meet our partners’ objectives.
Examples of programmes executed across various geographical regions are listed below. For more information, please contact FarmaMondo offices in your region or our Medical Affairs teams.
| Therapeutic area | Indications | Geographical scope |
|---|---|---|
| Oncology | Epithelial ovarian cancer / fallopian tube cancer | Targeted markets |
| Chemotherapy induced neutropenia | Targeted markets | |
| Haemato-oncology | Acute promyelocytic leukemia | Targeted markets |
| Multiple myeloma | Targeted markets | |
| Acute lymphoblastic leukemia (ALL) | Global | |
| Pediatric oncology/haematology | Neuroblastoma | Targeted markets |
| Metabolic disease orphan | Wilson's disease (orphan) | Targeted markets |
| Congenital or acquired generalized lipodystrophy | Targeted markets | |
| Homozygous familial hypercholesterolemia | Targeted markets | |
| Gaucher disease | Global | |
| Alagille syndrome (ALGS) | Targeted markets | |
| Progressive familial intrahepatic cholestasis (PFIC) | Targeted markets | |
| Neurology orphan | Allan-Herndon-Dudley syndrome | Targeted markets |
| Duchenne muscular dystrophy | Targeted markets | |
| Ophthalmology orphan | Neurotrophic keratitis | Targeted markets |
| Dermatology orphan | Epidermolysis bullosa (EB) | Targeted markets |
